-
-
-
-
-
-
-
Q32 Bio to present bempikibart trial data at EADV congress
-
-
-
-
-
-
-
Q32 Bio Inc. (QTTB) PT Raised to $36 at Mizuho
-
-
-
-
-
-
-
Mizuho Starts Q32 Bio Inc. (QTTB) at Outperform
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB)
-
-
-
-
-
-
-
Q32 Bio (QTTB) Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
-
-
-
-
-
-
-
Q32 Bio Inc. (QTTB) PT Slashed to $20 at Piper Sandler Following 'Messy' P2a Readouts
-
-
-
-
-
-
-
BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform
-
479,030 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


